Real Time Operating Systems (RTOS) for IoT: Market Analysis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Real Time Operating Systems (RTOS) for IoT: Market Analysis and Forecasts 2017-2022 Including Hardware, Software and Firmware

Dublin, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Real Time Operating Systems (RTOS) for IoT: Market Analysis and Forecasts 2017 - 2022" report to their offering.

A Real-time Operating Systems (RTOS) is an OS that manages hardware resources, hosts applications, and processes data on real-time basis. RTOS defines the real time task processing time, interrupt latency, and reliability of both hardware and applications, especially for low powered and memory constrained devices and networks.

The key difference between RTOS and a general purpose OS lies within its high degree of reliability and consistency on timing between application's task acceptance and completion.

RTOS is a critical component to build comprehensive embedded systems for Internet of Things (IoT) solutions for both consumer and industrial IoT (IIoT). Embedded RTOS is a key consideration to build mission critical, reliable IIoT applications across various industry verticals including industrial equipment, automotive, healthcare, telecommunications, government solutions, and more.

This research provides an in-depth assessment of the RTOS embedded IoT system market including following:

- Assessment of RTOS in IoT including hardware, software, and firmware
- Analysis of embedded RTOS programs to support low power network connectivity
- Evaluation of peripherals and tools to support processing of embedded systems in IoT
- Assessment of applications and industry verticals including benefits of RTOS over traditional OS
- Analysis of market segments and sub-segments with consideration towards emerging business models
- Evaluation of leading RTOS vendors, platforms, and solutions including both open source and proprietary

Forecasts included with this report address Market Segments, Sub-Segments, Application Sectors, and Business Models covering:


- Global and Regional RTOS Embedded IoT System market 2017 - 2022
- RTOS embedded connected IoT device shipment forecasts 2017 - 2022
- RTOS embedded component shipments by MCUs, MPUs, and MEMS 2017 - 2022
- Vendor market share of embedded RTOS software and RTOS embedded components

Key Topics Covered:

1 Introduction

2 RTOS Value Chain, Architecture, and Software Ecosystem

3 Embedded RTOS IOT Market and Forecasts

4 Embedded RTOS Shipment Forecasts

5 RTOS Platforms and Solutions

6 RTOS Software and Component Vendor Analysis

7 Conclusions and Recommendations

Companies Mentioned

  • AMD
  • Amperex Technology Ltd. (ATL)
  • Atari
  • Atmel Corporation
  • Blackberry Ltd
  • Emerson Network Power
  • ENEA
  • Express Logic, Inc.
  • Google
  • Huawei
  • IBM
  • IXYS Corporation
  • Johnson Controls Inc.
  • Johnson Matthey
  • LG Chem
  • Linux
  • Microchip Technology
  • Microsoft
  • NEC
  • Nuvoton
  • NXP Semiconductors
  • OAR corporation
  • OpenWSN
  • Panasonic Corp.
  • Samsung
  • Segger Microcontroller Systems
  • Sharp
  • SHHIC
  • Silicon Labs
  • Spansion
  • STMicroelectronics
  • Texas Instruments
  • TinyOS
  • Toshiba Corp
  • Xillinx

For more information about this report visit http://www.researchandmarkets.com/research/v24dvx/real_time


CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Internet of Things and M2M, Operating Systems , Programming Languages

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Protecting Shareholder Rights: iRhythm Technologies Update

Updated Category News Views 104

Understanding Your Rights as a Shareholder For shareholders of iRhythm Technologies, Inc. (NASDAQ: IRTC), it's imperative to be proactive regarding your rights. Engaging with legal experts can significantly empower your ability to affect change and seek justice for any personal or collective grievances stemming from corporate actions. Why Shareholder Action is Crucial...

Continue Reading
Discover the New Credit Risk IQ and its Industry Insights

Updated Category News Views 138

Introducing Credit Risk IQ Credit Benchmark, a leader in delivering essential credit risk data and analytics, has launched an exciting new platform called Credit Risk IQ. This online portal features an extensive library of over 5,000 free monthly reports that explore credit trends at both industry and sector levels. The insights found in these reports are invaluable for...

Continue Reading
9Rooftops Retained as Marketing Agency for South Carolina Tourism

Updated Category News Views 233

9Rooftops Reappointed for South Carolina Tourism Marketing 9Rooftops, known for its innovative marketing strategies, has been reappointed as the Marketing and Advertising Agency of Record for the South Carolina Department of Parks, Recreation & Tourism (SCPRT). This marks a continued partnership aimed at showcasing the beauty and attractions of South Carolina. A...

Continue Reading
Kyivstar Enhances Digital Services with AI Cloud Solutions

Updated Category News Views 203

Kyivstar Revolutionizes Cloud Services with AI Integration Kyivstar Group Ltd (Nasdaq: KYIV; KYIVW) has embarked on an ambitious journey to strengthen digital services within Ukraine. The company has officially announced the integration of groundbreaking artificial intelligence (AI) technologies into its cloud platform, Kyivstar Cloud. This advancement is pivotal for all...

Continue Reading
Akeso Advances Cancer Care with Ivonescimab Phase III Trial Launch

Updated Category News Views 171

Akeso Launches Phase III Trial for Ivonescimab in SCLC Akeso, Inc. (9926.HK) recently announced an exciting milestone in cancer treatment with the first patient being dosed in its Phase III clinical trial. This multicenter, randomized, and double-blind study, named AK112-311/HARMONi-9, evaluates the efficacy and safety of ivonescimab, a unique bispecific antibody that...

Continue Reading